Bank of Montreal’s Climb Bio CLYM Stock Holding History

Bank of Montreal’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,244	Closed	-$92.6K	–	4266
2022 Q4	$92.6K	Buy	+25,244	New	+$74.9K	﹤0.01%	3380

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of Montreal's CLYM Position: Q1 2023 in Review

Bank of Montreal sold out of Climb Bio (CLYM) in Q1 2023, closing a stake of 25,244 shares — an estimated $92.6K sold.

Bank of Montreal first reported a position in CLYM in Q4 2022 and held it in 1 quarter. The position peaked at $92.6K in Q4 2022. 19 funds tracked by Wall St. Rank hold CLYM as of Q1 2023.

Bank of Montreal reported no remaining Climb Bio position as of Q1 2023 after selling out during the quarter.
Bank of Montreal sold 25,244 Climb Bio shares in Q1 2023, an estimated $92.6K.
Bank of Montreal first reported a position in Climb Bio in Q4 2022 and held it in 1 quarter.
Bank of Montreal's Climb Bio position peaked at $92.6K in Q4 2022.
19 funds tracked by Wall St. Rank held Climb Bio as of Q1 2023.

Based on Bank of Montreal's 13F filing for Q1 2023, filed 13 Jun 2024.